Pacific Biosciences was among the stocks ARK funds bought, showing investor interest. The report gives no new company results or plans, so its business outlook is unchanged.
The purchases show ARK chose to hold more PACB shares, but the report gives no new company results or plans. It describes the trades as part of the firm's ongoing fund management, so they do not change PACB's business outlook.
Illumina was named among the companies ARK added to its holdings. The report gives no new company results or plans, so its business outlook is unchanged.
Beam Therapeutics was named among the companies ARK added to its holdings. The report gives no new company results or plans, so its business outlook is unchanged.
Arcturus Therapeutics was named among the companies ARK added to its holdings. The report gives no new company results or plans, so its business outlook is unchanged.
Follow Pacific Biosciences of California, Inc. (PACB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PACB